- Home
- CMMB vs PHIO Comparison
CMMB vs PHIO Comparison
Compare CMMB & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- PHIO
- Stock Information
- Founded
- CMMB 2004
- PHIO 2011
- Country
- CMMB Israel
- PHIO United States
- Employees
- CMMB N/A
- PHIO N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- PHIO Health Care
- Exchange
- CMMB Nasdaq
- PHIO Nasdaq
- Market Cap
- CMMB 13.7M
- PHIO 13.5M
- IPO Year
- CMMB N/A
- PHIO N/A
- Fundamental
- Price
- CMMB $3.28
- PHIO $2.12
- Analyst Decision
- CMMB Strong Buy
- PHIO Strong Buy
- Analyst Count
- CMMB 2
- PHIO 3
- Target Price
- CMMB $26.50
- PHIO $10.67
- AVG Volume (30 Days)
- CMMB 260.4K
- PHIO 139.3K
- Earning Date
- CMMB 11-13-2025
- PHIO 11-13-2025
- Dividend Yield
- CMMB N/A
- PHIO N/A
- EPS Growth
- CMMB N/A
- PHIO N/A
- EPS
- CMMB N/A
- PHIO N/A
- Revenue
- CMMB N/A
- PHIO N/A
- Revenue This Year
- CMMB N/A
- PHIO N/A
- Revenue Next Year
- CMMB N/A
- PHIO N/A
- P/E Ratio
- CMMB N/A
- PHIO N/A
- Revenue Growth
- CMMB N/A
- PHIO N/A
- 52 Week Low
- CMMB $2.39
- PHIO $0.97
- 52 Week High
- CMMB $9.84
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- CMMB 59.76
- PHIO 42.31
- Support Level
- CMMB $3.03
- PHIO $2.07
- Resistance Level
- CMMB $3.50
- PHIO $2.45
- Average True Range (ATR)
- CMMB 0.21
- PHIO 0.13
- MACD
- CMMB 0.02
- PHIO -0.03
- Stochastic Oscillator
- CMMB 64.21
- PHIO 10.19
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.